Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
- 2k Downloads
In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK rearrangements represent the molecular driver of a subset of solid tumors, including 3% of non-small-cell lung cancers (NSCLCs). Preliminary data indicate that molecularly selected NSCLC patients harboring NTRK fusions derive an unprecedented clinical benefit from Trk-directed targeted therapies. The aim of this review is to describe the molecular biology of NTRK signaling pathway and to summarize the preclinical data on novel Trk inhibitors, touching upon the clinical development of these inhibitors for the treatment of advanced NSCLC, which have already shown encouraging anticancer activity and acceptable safety profile in early phase I clinical trials.
KeywordsNSCLC NTRK mutations Entrectinib LOXO-101
Supported by the Italian Association for Cancer Research (AIRC).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was not required as this article does not contain any studies with human participants.
- 2.American Cancer Society. Non-small cell lung cancer survival rates by stage. https://www.cancer.org/cancer/lungcancernonsmallcell/detaileddpfguide/non-small-cell-lung-cancer-survival-rates. Accessed 01 Feb 2017.
- 7.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMedGoogle Scholar
- 9.Yang JCH, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–51.CrossRefPubMedGoogle Scholar
- 12.Nokihara H, Hida T, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK inhibitor naive ALK-positive non-small cell lung cancer (ALK + NSCLC): Primary results from the J-ALEX study. J Clin Oncol. 2016;34(S5):9008 (abstract).Google Scholar
- 31.Varella-Garcia M, Kako S, Nguyen C, et al. FISHing TRK activation by gene rearrangements in non small cell lung cancer. J Thorac Oncol. 2015;10:9 (abstract: 3701).Google Scholar
- 32.Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014;2:725–30.PubMedPubMedCentralGoogle Scholar
- 40.Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014;2(5):725–30.PubMedPubMedCentralGoogle Scholar
- 41.De Braud FG, Niger M, Damian S, Bardazza B, Martinetti A, Pelosi G, et al. Alka-372-001: first-in-human, phase I study of entrectinib—an oral pan-trk, ROS1, and ALK inhibitor—in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2015;33(suppl; abstr 2517).Google Scholar
- 42.Patel MR, Bauer TM, Liu SV, Drilon AE, Wheler JJ, Shaw AT, et al. STARTRK-1: phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2015; 33(suppl; abstr 2596).Google Scholar
- 43.Burris HA, Brose MS, Shaw AT, Bauer TM, Farago AF, Doebele RC, et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J Clin Oncol 2015;33(suppl; abstr TPS2624).Google Scholar